Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Korea Drug Development Fund has granted funds to SK Biopharmaceuticals to support clinical development of the lead drug, YKP3089, for the next three years.
Subscribe to our email newsletter
The funding support received will be used by the company to support global late Phase 2 clinical trials in refractory epilepsy.
YKP3089 was discovered initially to have a broad spectrum of action in animal models of epilepsy and seizure disorders.
SK Biopharmaceuticals drug development business vice president Jeong Woo Cho said if the company’s Phase II and Phase III clinical trials go smoothly, it will be able to market the drug in 2017.
"The worldwide neuropathic pain market is $2.5 billion in size, and if YKP3089 shows efficacy in various types of this pain, the value of the drug will be tremendous," Dr. Cho added.